Denosumab reduces early migration in total knee replacement

Figures & data

Figure 1. Flow diagram of participants.

Table 1. Patient characteristics

	Denosumab (n = 25)	Placebo (n = 25)
Male/Female	10/15	10/15
Age, mean (SD)	66 (6.3)	64 (5.5)
BMI, mean (SD)	30 (5.2)	28 (3.7)

Figure 2. RSA maximal total point motion (MTPM) migration in mm. Data for 12 months were the primary effect variable. Line in boxes indicate median values, boxes interquartile range, and whiskers total range.

Figure 3. RSA maximal total point motion migration (MTPM) in mm between 12 and 24 months. Horizontal lines indicate median values.